ATE529444T1 - Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten - Google Patents

Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Info

Publication number
ATE529444T1
ATE529444T1 AT04022346T AT04022346T ATE529444T1 AT E529444 T1 ATE529444 T1 AT E529444T1 AT 04022346 T AT04022346 T AT 04022346T AT 04022346 T AT04022346 T AT 04022346T AT E529444 T1 ATE529444 T1 AT E529444T1
Authority
AT
Austria
Prior art keywords
kunitz domains
human plasmin
inhibitors derived
plasmin inhibitors
nucleic acids
Prior art date
Application number
AT04022346T
Other languages
English (en)
Inventor
William Markland
Robert Charles Ladner
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE529444T1 publication Critical patent/ATE529444T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/515—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics
    • C04B35/58—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides
    • C04B35/584—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride
    • C04B35/593—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering
    • C04B35/5935—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering obtained by gas pressure sintering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Structural Engineering (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Amplifiers (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
AT04022346T 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten ATE529444T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17965894A 1994-01-11 1994-01-11
US20826594A 1994-03-10 1994-03-10

Publications (1)

Publication Number Publication Date
ATE529444T1 true ATE529444T1 (de) 2011-11-15

Family

ID=26875521

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95908460T ATE277081T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
AT04022346T ATE529444T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95908460T ATE277081T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Country Status (10)

Country Link
US (11) US6010880A (de)
EP (2) EP1489097B1 (de)
JP (5) JP4137997B2 (de)
AT (2) ATE277081T1 (de)
CA (1) CA2180954C (de)
DE (1) DE69533544T2 (de)
DK (2) DK1489097T3 (de)
ES (2) ES2229236T3 (de)
PT (2) PT1489097E (de)
WO (1) WO1995018830A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040224A1 (en) * 1995-06-07 1996-12-19 Chiron Corporation Regulation of cytokine synthesis and release
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
EP0963435B1 (de) 1997-01-08 2008-05-28 Invitrogen Corporation Verfahren zur herstellung von proteinen
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US20020076728A1 (en) * 1997-03-21 2002-06-20 Maclennan John Moore Engineering affinity ligands for macromolecules
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
CA2342072C (en) * 1998-09-03 2005-01-11 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US5994310A (en) * 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US6380354B1 (en) 1998-09-03 2002-04-30 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20030032146A1 (en) * 2001-07-10 2003-02-13 Dwulet Francis Edward Enzyme/tag binding and detection system
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (de) 2002-08-28 2018-11-07 Dyax Corp. Verfahren zur Erhaltung von Organen und Geweben
DK1587907T3 (da) * 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
AU2004268144A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7740973B2 (en) * 2004-08-05 2010-06-22 General Motors Corporation Modular electrochemical power system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (de) * 2004-11-22 2009-04-01 Dyax Corp Plasmin-hemmende therapien
EP1858542A4 (de) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Zusammensetzungen und verfahren zur behandlung von gefässpermeabilität
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
EP3088522B1 (de) * 2005-12-29 2017-11-29 The Regents of the University of California Verfahren und zusammensetzungen in verbindung mit mutanter kunitz-domäne i von tfpi-2
AU2013202021B2 (en) * 2005-12-29 2016-03-10 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain of TFPI-2
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
CN101395274A (zh) * 2006-03-08 2009-03-25 拜耳医药保健股份公司 嵌合Kunitz结构域及其用途
EP2001500A4 (de) * 2006-03-10 2010-07-28 Dyax Corp Formulierungen für ecallantid
PL2374472T3 (pl) 2006-03-16 2018-11-30 Dyax Corp. Kompozycje i sposoby leczenia zaburzeń okulistycznych
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
NO2344540T3 (de) 2008-10-02 2018-04-28
AU2009303318B2 (en) * 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
JP6509724B2 (ja) 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
US10550154B2 (en) 2012-08-08 2020-02-04 Daiichi Sankyo Company, Limited Peptide library and use thereof
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
EP2970434B1 (de) * 2013-03-15 2018-12-05 The Regents of The University of California Potenter kunitz-inhibitor der fibrinolyse mit dualer reaktivität
EP3925618A1 (de) 2013-07-29 2021-12-22 2seventy bio, Inc. Multilaterale signalisierungsproteine und verwendungen davon
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
EP4406604A3 (de) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunmodulatorische fusionsproteine und verwendungen davon
EP3288570A4 (de) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modifizierte stammzellen und verwendungen davon
EP3288569A4 (de) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modifizierte hämatopoietische stamm-/vorläuferzellen und non-t effektorzellen sowie verwendungen davon
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3387018A1 (de) 2015-12-11 2018-10-17 Dyax Corp. Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
EP3430058A4 (de) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Multispezifische fab-fusionsproteine und verwendungen davon
EP4711465A2 (de) 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Zusammensetzungen und verfahren zur programmierung therapeutischer zellen unter verwendung gezielter nukleinsäurenanoträger
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
CA3084551A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
EP3847196A4 (de) 2018-09-07 2023-01-04 ITabMed (HK) Limited Bispezifische antigenbindende proteine und verwendungen davon
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
KR20210104772A (ko) 2018-12-14 2021-08-25 블루버드 바이오, 인코포레이티드. 이량체화제로 조절된 면역수용체 복합체
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
KR20220031549A (ko) 2019-05-08 2022-03-11 2세븐티 바이오, 인코포레이티드 Cll-1 표적화 면역요법
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
EP4090427A1 (de) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma-kallikrein-inhibitoren und verwendungen davon zur pädiatrischen behandlung von hereditärem angioödem
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN120230192B (zh) * 2025-03-18 2025-10-24 中山大学 一种丽鱼三代虫重组kunitz蛋白及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
DK0401508T3 (da) * 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5278285A (en) 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
CA2055425A1 (en) 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
EP0637643A3 (de) * 1991-06-28 1995-04-19 Wecotec Ltd Überführung von Tüchern.
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
WO1994012637A2 (en) * 1992-12-02 1994-06-09 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
CN1200036A (zh) 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
AU1210797A (en) 1996-01-08 1997-08-01 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor
JP3357807B2 (ja) * 1997-01-13 2002-12-16 株式会社東芝 受信装置および移相器
US7383135B1 (en) * 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
JP2000106882A (ja) 1998-10-02 2000-04-18 Chemo Sero Therapeut Res Inst 癌転移増殖抑制作用を有する血漿蛋白断片産生酵素および当該酵素により断片化された血漿蛋白断片
EP1243276A1 (de) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
EP1390497A2 (de) 2001-05-25 2004-02-25 Genset Menschliche cdns und proteine und verwendungen davon
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
EP2386310B1 (de) 2002-08-28 2018-11-07 Dyax Corp. Verfahren zur Erhaltung von Organen und Geweben
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
DK1587907T3 (da) * 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors

Also Published As

Publication number Publication date
JP2008113657A (ja) 2008-05-22
US6103499A (en) 2000-08-15
DE69533544D1 (de) 2004-10-28
US7919462B2 (en) 2011-04-05
JP2013249302A (ja) 2013-12-12
US8431359B2 (en) 2013-04-30
EP0737207A1 (de) 1996-10-16
US6071723A (en) 2000-06-06
US6953674B2 (en) 2005-10-11
DK0737207T3 (da) 2005-01-31
ES2229236T3 (es) 2005-04-16
US20090023651A1 (en) 2009-01-22
PT737207E (pt) 2005-02-28
US20090036365A1 (en) 2009-02-05
JP2009183281A (ja) 2009-08-20
CA2180954C (en) 2007-03-20
DE69533544T2 (de) 2006-02-23
CA2180954A1 (en) 1995-07-13
US20110152193A1 (en) 2011-06-23
JP4137997B2 (ja) 2008-08-20
DK1489097T3 (da) 2012-01-09
WO1995018830A3 (en) 1995-08-10
US20050186649A1 (en) 2005-08-25
JP2012111779A (ja) 2012-06-14
US20090036366A1 (en) 2009-02-05
US20030165896A1 (en) 2003-09-04
US6423498B1 (en) 2002-07-23
EP1489097A1 (de) 2004-12-22
PT1489097E (pt) 2012-01-04
EP0737207B1 (de) 2004-09-22
US6010880A (en) 2000-01-04
ES2375561T3 (es) 2012-03-02
ATE277081T1 (de) 2004-10-15
WO1995018830A2 (en) 1995-07-13
EP1489097B1 (de) 2011-10-19
JPH09509048A (ja) 1997-09-16
US20080182283A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
ATE529444T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
ATE239079T1 (de) Gewebeinhibitor für metalloproteasen type 3 (timp-3)
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
ATE226634T1 (de) Fibronektin bindendes protein
EP0205475A4 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
MXPA02008239A (es) Gen humano de la esquizofrenia.
DK0817851T5 (da) DNA, der koder for humant papillomvirus type 18
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO2001064876A3 (en) Human schizophrenia gene
NO973876L (no) Human-DNase I-varianter
SE9604439D0 (sv) New receptor
EP1679372A4 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
DK0386733T3 (da) cDNA, som koder for placentaprotein 9 (PP9), dets isolering og anvendelse
BG101847A (bg) Варианти на човешка дезоксирибонуклеаза i
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1489097

Country of ref document: EP